Adaptive Biotechnologies
Adaptive Biotechnologies Raises Revenue Guidance as Momentum Builds in Q1 for MRD Testing
The firm now expects FY 2025 MRD revenues in the range of $180 million to $190 million, implying annual growth of 24 percent to 31 percent.
Adaptive Biotechnologies Wins Expanded Medicare Coverage of ClonoSeq in Mantle Cell Lymphoma
The expanded coverage adds to the existing Medicare payment structure for ClonoSeq, which provides coverage for a bundle of tests to assess patient therapy response.
GenomeWeb Top 40 Plummets 14 Percent in February as Government Spending Concerns Loom
The Dow Jones Industrial Average fell 2 percent, the Nasdaq fell 4 percent, and the Nasdaq Biotech Index declined by less than 1 percent.
Adaptive Bio 'Confident' of MRD Reaching Profitability in 2025 as Q4 Revenues Rise 4 Percent
Premium
The Seattle-based firm booked $47.5 million in revenues during the fourth quarter while full-year revenues grew 5 percent to $179.0 million.
JP Morgan Healthcare Conference, Day 2: CareDx, Thermo Fisher, BillionToOne, Adaptive Biotech, More
Highlights from the second day included BillionToOne's 2024 revenue spike and CareDx's plan to expand indications for its transplant tests.